Evidence map›Paper›PMID 24821751›Full record

ReviewNephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association2015

Iron dosing in kidney disease: inconsistency of evidence and clinical practice.

Adam E Gaweda, Yelena Z Ginzburg, Yossi Chait, Michael J Germain, George R Aronoff, Eliezer Rachmilewitz

Registry-linked trialOpen access · bronzeAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03005847 (The Effect of Fermented Papaya Preparation on Patients With Chronic Kidney Disease Under Dialysis Receiving Intravenous Iron), which is not on this map. Cited by 13 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed, 1 pooled it
3.1field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT03005847 naunknown statusnot on this mapstarted 2017, after this paper: background citation

The Effect of Fermented Papaya Preparation on Patients With Chronic Kidney Disease Under Dialysis Receiving Intravenous Iron

TypeinterventionalSponsorHadassah Medical OrganizationRan2017Enrolled20ConditionsAnemia, Chronic Kidney Disease Stage 5Armsfermented papaya preparation
3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 1 synthesis or guideline pooled it, 38 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Article
  4. Review
  5. Review
  6. Observational
  7. Review
  8. Safety of intravenous iron in hemodialysis patients.Hemodialysis international. International Symposium on Home Hemodialysis · 2017
    Review
  9. Iron Therapy Challenges for the Treatment of Nondialysis CKD Patients.Clinical journal of the American Society of Nephrology : CJASN · 2016
    Review
  10. Review
  11. Article
  12. Article
  13. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 5 institutions in 2 countries.

Adam E GawedaUniversity of Louisville, Louisville KY, USA.
Yelena Z GinzburgNew York Blood Center, New York, NY, USA.
Yossi ChaitUniversity of Massachusetts, Amherst, MA, USA.
Michael J GermainBaystate Medical Center, Tufts University School of Medicine, Boston, MA, USA.
George R AronoffUniversity of Louisville, Louisville KY, USA.
Eliezer RachmilewitzThe Edith Wolfson Medical Center, Holon, Israel.
University of Louisville · USNew York Blood Center · USTufts University · USUniversity of Massachusetts Amherst · USWolfson Medical Center · IL

Funding

Computational Approach to Personalized Anemia ManagementR01DK093832 · NIDDK · UNIVERSITY OF LOUISVILLE · PI GAWEDA, ADAM E · 2012 to 2015
$1.8M
The Engineering of Individualized Anemia Management ProtocolsK25DK096006 · NIDDK · UNIVERSITY OF MASSACHUSETTS AMHERST · PI CHAIT, YOSSI · 2013 to 2016
$670k
NIDDK NIH HHS K25 DK096006NIDDK NIH HHS K25DK09600601NIDDK NIH HHS R01 DK093832NIDDK NIH HHS R01DK093832
6 · The paper itself

Abstract

The management of anemia in patients with chronic kidney disease (CKD) is difficult. The availability of erythropoiesis-stimulating agents (ESAs) has increased treatment options for previously transfusion-requiring patients, but the recent evidence of ESA side effects has prompted the search for complementary or alternative approaches. Next to ESA, parenteral iron supplementation is the second main form of anemia treatment. However, as of now, no systematic approach has been proposed to balance the concurrent administration of both agents according to individual patient's needs. Furthermore, the potential risks of excessive iron dosing remain a topic of controversy. How, when and whether to monitor CKD patients for potential iron overload remain to be elucidated. This review addresses the question of risk and benefit of iron administration in CKD, highlights the evidence supporting current practice, provides an overview of standard and potential new markers of iron status and outlines a new pharmacometric approach to physiologically compatible individualized dosing of ESA and iron in CKD patients.

Indexed as

Anemia, Iron-DeficiencyErythropoietinHematinicsHumansIron CompoundsIron OverloadRenal Insufficiency, ChronicErythropoietinHematinicsIron Compoundsanemiaerythropoiesisironiron deficiencyiron overloadkidney disease

Identifiers

PMID24821751
PMCPMC4309189
OpenAlexW2132536044

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.